NCT04500665
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 10 versions: 9 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial terminated Sponsor's reason: Funding Show 4 more changesShow less
- Eligibility criteria expanded, about 30 words
- Final enrollment: 4 participants (planned 20)
- Primary completion date changed from estimate of Jul 31, 2026 to Nov 13, 2026
- Site details revised
- Notable Primary completion date: Dec 31, 2025 to Jul 31, 2026v9
- Notable Eligibility criteria shortened, about 3 wordsv8
- Notable Primary completion date: Dec 31, 2024 to Dec 31, 2025
- Eligibility criteria shortened, about 74 words
- Study completion date: Nov 11, 2025 to Nov 11, 2026
- Notable Eligibility criteria shortened, about 50 wordsv5
Show 3 earlier versionsHide 3 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Eligibility criteria expanded, about 101 words
- Start date changed from estimate of Sep 2021 to Nov 1, 2021
- Site details revised
- Notable Start date: Feb 1, 2021 to Sep 2021
- Study sites: 0 to 1
- Notable Start date: Oct 1, 2020 to Feb 1, 2021v2
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
Endpoints
Primary
Between-group change in left ventricular global longitudinal strain
Timeframe: 4 weeks
Secondary (4)
Between-group change in left ventricular systolic and diastolic function
Between-group change in left ventricular volumes
Between-group change in left ventricular size
Between-group change in systemic inflammation
Arms and interventions
ColchicineExperimental
Colchicine 0.3 mg once daily
PlaceboPlacebo comparator
Placebo once daily
Drugs: Colchicine, Placebo
Sites
1 site in 1 country
- Brigham and Women's HospitalBoston, Massachusetts, United States